Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Practical Selection of Novel Therapy for Relapsed/Refractory Follicular Lymphoma

December 6th 2022

Insight to the factors that help select optimal third-line treatment for patients with follicular lymphoma in the context of available novel therapies.

Leading by Example

December 3rd 2022

A girl who grew up in a small South Dakota town, Julie M. Vose, MD, MBA, grew into a dynamo who revolutionized lymphoma treatment and led the most prominent oncology organization in the world.

PI3K Inhibitors Face Challenges in Hematologic Malignancies

December 2nd 2022

The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under scrutiny amid concerns about efficacy and safety.

FDA Approves Olutasidenib for IDH1-Mutated Relapsed/Refractory AML

December 1st 2022

The FDA has approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test.

FDA Accepts BLA of Denileukin Diftitox Reformulation for Persistent or Recurrent Cutaneous T-cell Lymphoma

December 1st 2022

The FDA has accepted a biologics license application seeking the approval of a reformulation of denileukin diftitox for use as a potential therapeutic option in patients with persistent or recurrent cutaneous T-cell lymphoma.

Novel Third-Line Therapies for Relapsed/Refractory Follicular Lymphoma

November 30th 2022

A comprehensive overview of the third-line treatment armamentarium for patients with relapsed/refractory follicular lymphoma.

Relapsed/Refractory Follicular Lymphoma: Sequencing Through Multiple Lines of Therapy

November 30th 2022

Key opinion leader Lori Leslie, MD, sheds light on the optimal sequencing of therapy throughout multiple lines of follicular lymphoma.

Dr. Brody on Updated Data From the ECHELON-1 Trial in Hodgkin Lymphoma

November 29th 2022

Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.

FDA Grants RMAT, Fast Track Designations to CB-010 in Relapsed/Refractory Non-Hodgkin Lymphoma

November 29th 2022

The FDA has granted CB-010 a regenerative medicine advanced therapy designation for relapsed/refractory large B-cell lymphoma and a fast track designation for relapsed/refractory B-cell non-Hodgkin lymphoma.

FDA Extends PDUFA Date for BLA of Omidubicel in Blood Cancers Requiring Transplant

November 23rd 2022

The FDA has extended the Prescription Drug User Fee Act goal date to May 1, 2023, for the biologics license application seeking the approval of omidubicel for patients with blood cancers in need of allogenic hematopoietic stem cell transplant.

Assessing Response to Therapy and High-Risk Disease in Follicular Lymphoma

November 23rd 2022

An expert’s perspective on assessing response to therapy in follicular lymphoma and the parameters used to identify high-risk disease.

Overview on Follicular Lymphoma and A Patient Case of Relapsed/Refractory Disease

November 23rd 2022

Expert hematologist-oncologist Lori Leslie, MD, provides insight to the incidence and prognosis of follicular lymphoma, highlighting a patient case of refractory disease.

Zandelisib Elicits High Response Rates in Indolent Non-Hodgkin Lymphoma

November 21st 2022

The oral PI3Kδ inhibitor zandelisib produced an overall response rate in Japanese patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma without small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and Waldenström macroglobulinemia.

FDA Approves Additional Dosing Schedule for Rylaze in ALL and LBL

November 18th 2022

The FDA has approved a supplemental biologics license application to add a Monday/Wednesday/Friday intramuscular dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze).

Ponatinib Provides Higher Rate of MRD-negative CR Vs Imatinib in Newly Diagnosed Ph+ ALL

November 17th 2022

Ponatinib plus reduced-intensity chemotherapy produced a higher rate of minimal residual disease–negative complete remission compared with imatinib in patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Evolving Treatments Seek to Address Unanswered Questions in Hematologic Malignancies

November 16th 2022

Novel agents such as momelotinib and pacritinib are expanding the myelofibrosis treatment landscape, and additional research will further define the options available for patients with this disease, as well as those with other leukemias and lymphomas.

Dr. Perl on Genetic Testing and Targeted Therapies in AML

November 10th 2022

Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

In this inaugural episode, Dr Lunning details important findings to come out of the Pan Pacific Lymphoma Conference, including results evaluating prophylactic medications in the management of patients with hematologic malignancies receiving cellular therapy or autologous stem cell transplant.

FDA Approves Brentuximab Vedotin for Pediatric Patients With Previously Untreated, High-risk Hodgkin Lymphoma

November 10th 2022

The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in pediatric patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma.

Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

November 9th 2022

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line.